Nightingale Health Plc
Company release
18 December 2024 at 9:35 p.m. (EET)

Nightingale Health Plc (“Nightingale Health”) has entered into a Liquidity Providing (LP) agreement with Lago Kapital Ltd (“Lago”) within the framework of Nasdaq First North Growth Market rules for liquidity provision.

According to the agreement, Lago will quote bids and offers for Nightingale Health's share in such a way that the spread of the bid and offer prices is a maximum of 3% calculated from the bid price. The quotes on bid and offer must be at least EUR 3,000 worth of shares.

Lago shall quote bids and offers for Nightingale Health's share in the trading system of Nasdaq Helsinki on each trading day for at least 85% of the continuous trading period.

Liquidity providing in accordance with the agreement will commence on 19 December 2024. The agreement will be in force initially for a fixed term of three months and thereafter until further notice with a notice period of one month.

The intention is to promote liquidity in the share and decrease the share price volatility.

To support the liquidity providing, Cor Group Oy has lent 10,000 Nightingale Health's shares to Lago.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Finland Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/